Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More
Voltas, Navneet Education and Kotak Mahindra Bank are on the watch list of analysts. Meanwhile, insurance, pharma and autos are also in focus.
Sudarshan Sukhani of s2analytics.com is of the view that one can buy IndusInd Bank, Bajaj Finance and Tata Chemicals and sell ACC and Glenmark Pharma.
Sudarshan Sukhani of s2analytics.com is of the view that one can sell India Cements and Glenmark Pharma and buy HDFC.
Sudarshan Sukhani of s2analytics.com suggests selling Tata Motors and Glenmark Pharma and advises buying Colgate Palmolive.
In an interview to CNBC-TV18's Latha Venkatesh, Sonia Shenoy and Anuj Singhal, SP Tulsian of sptulsian.com shared his reading and outlook on the market and also gave recommendations on various stocks.
Mitessh Thakkar of miteshthacker.com is of the view that one can buy Colgate Palmolive, Dishman Pharmaceuticals and Future Consumer and sell Engineers India and Glenmark Pharma.
In an interview to CNBC-TV18 SP Tulsian, sptulsian.com shared his reading and outlook on the market and also gave recommendations on various stocks.
In an interview to CNBC-TV18's Latha Venkatesh, Sonia Shenoy and Anuj Singhal, Sanjiv Bhasin of IIFL shared his reading and outlook on the market and also gave recommendations on various stocks.
Easing regulatory concerns and actions by the US Food and Drug Administration (FDA) will help the sector and improve investor sentiment, Deutsche Bank said in a report.
Ashwani Gujral of ashwanigujral.com is of the view that one can buy Just Dial and sell Container Corporation of India and Glenmark Pharma.
Sandeep Wagle of powermywealth.com is of the view that one can buy Adani Enterprises and Indraprastha Gas and advises selling Glenmark Pharma.
In an interview to CNBC-TV18, Dipan Mehta, Member of BSE & NSE shared his readings and outlook on specific stocks and sector.
Vijay Chopra of enochventures.com is of the view that one may hold Cipla.
Mitessh Thakkar of miteshthacker.com is of the view that one may buy Glenmark Pharma, Snowman Logistics, BGR Energy and Suven Life Sciences and sell MRF.
According to Prakash Gaba of prakashgaba.com, Bata India looks good for target Rs 525 and feels that Lupin can go up and test Rs 1800.
In an interview to CNBC-TV18's Latha Venkatesh, Sonia Shenoy and Anuj Singhal, Prakash Diwan of Altamount Capital Management shared his reading and outlook on the market and also gave recommendations on various stocks.
Mitessh Thakkar of miteshthacker.com suggests buying Indiabulls Housing Finance, Reliance Communications, Oriental Bank of Commerce and Andhra Bank.
According to Ashwani Gujral of ashwanigujral.com, one can buy Sun TV, Ujjivan Financial Services, Glenmark Pharma and Bajaj Finserv.
"In 180 day exclusivity period in anti-diabetic drug in US market, Glenmark recorded superlative performance with more than 100 percent growth. I believe that the stock holds promise to grow between 30 percent and 40 percent upside in next 12-18 months time", Deven Choksey of KRChoksey Investment Managers told CNBC-TV18.
CLSA says special court verdict on former Telecom Minister Dayanidhi Maran and his brother & head of the company Kalanidhi Maran, in Aircel-Maxis case, ended long-standing legal overhang on the company. The brokerage house has upgraded the stock to buy from sell and raised target price to Rs 661 from Rs 438.
Yogesh Mehta of Motilal Oswal Securities suggests buying Federal Bank, Glenmark Pharma and Divis Laboratories.
According to Vijay Chopra of enochventures.com, one may exit Glenmark Pharma at Rs 950.
Rajat Bose of rajatkbose.com feels that Glenmark Pharma may touch Rs 1000.
Mitessh Thakkar of miteshthacker.com recommends buying Just Dial, Glenmark Pharma and NCC.